Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Research output: Contribution to journalJournal articleResearch

  1. The effect of antidepressants on brain volume

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nyt studie viser, at motion beskytter mod depression

    Research output: Contribution to journalContribution to newspaper - Comment/debateCommunication

  3. Forebyggelse og behandling af cytomegalovirusinfektion hos gravide og nyfødte

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Groin hernia in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Boganmeldelse: Min mor var besat

    Research output: Contribution to journalContribution to newspaper - ReviewCommunication

  1. Statin treatment, oxidative stress and inflammation in a Danish population

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Eosinofili

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reconstitution of Th17, Tc17 and Treg cells after paediatric haematopoietic stem cell transplantation: Impact of interleukin-7

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.
Translated title of the contribution[Rituximab (MabThera) as treatment of active rheumatoid arthritis]
Original languageDanish
JournalUgeskrift for Laeger
Volume168
Issue number47
Pages (from-to)4079-81
Number of pages3
Publication statusPublished - 20 Nov 2006

ID: 31052506